# Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

> **NCT00801060** · PHASE2 · TERMINATED · sponsor: **Biogen** · enrollment: 40 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Lumiliximab + FCR
- **DRUG:** FCR

## Key facts

- **NCT ID:** NCT00801060
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2010-06
- **Final completion:** 2010-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00801060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00801060, "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00801060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*